ProKidney Corp. (BMV:PROK)

Mexico flag Mexico · Delayed Price · Currency is MXN
33.71
+1.47 (4.56%)
At close: Feb 9, 2026
Market Cap4.84B +8.8%
Revenue (ttm)13.65M
Net Income-1.30B
EPS-9.97
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,747
Average Volume11,409
Open32.10
Previous Close32.24
Day's Range32.10 - 33.71
52-Week Range12.18 - 132.00
Betan/a
RSI36.10
Earnings DateMar 18, 2026

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 204
Stock Exchange Mexican Stock Exchange
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements